By Justice — Elevated Club NYC The cannabis industry is no longer in its hype phase. What we’re seeing now—across insights from Cannabis Business Times  and broader market data—is a shift into something more serious: a disciplined, competitive, and maturing marketplace. 2026 is shaping up to be the year cannabis businesses either evolve—or get left behind. At the core of this shift is operational discipline. Companies are no longer surviving off demand alone. The industry is stabilizing, and success now depends on execution, efficiency, and long-term strategy. Operators are being forced to build real businesses—not just brands—with systems that can scale, survive audits, and eventually attract investment or acquisition opportunities. We’re also seeing a major focus on post-harvest quality and cultivation technology. It’s no longer just about growing good flower—it’s about consistency, preservation, and delivering a repeatable product experience. This is where premium brands will separate themselves from the rest. At the same time, pricing pressure is hitting the market hard. States like Colorado are already experiencing record-low cannabis prices due to oversupply and competition.  That reality is spreading. Margins are shrinking, and only the most efficient operators will survive. Regulation is another defining factor. From potential federal rescheduling to stricter state-level compliance, cannabis is entering a new phase of scrutiny. Businesses must be built to handle compliance like a core function—not an afterthought. And then there’s the consumer. Today’s cannabis buyer is more educated, more selective, and more intentional. People care about terpene profiles, cultivation methods, and product transparency. Trends like low-dose THC, functional cannabis, and wellness-driven products are gaining traction, showing that the market is expanding beyond just getting high. Even more telling—nearly 25% of cannabis sales are now happening online, signaling a shift toward convenience and digital-first experiences. For Elevated Club NYC, this moment is an opportunity. While the industry matures, we stay focused on what matters: quality, trust, and consistency. No storefront. No confusion. Just a direct-to-you experience built for New York. Because in a market that’s growing up fast, the brands that win won’t be the loudest—they’ll be the most reliable.

New York’s cannabis market continues to evolve, but not always in loud, headline-grabbing ways. The latest move out of Albany—a Senate-approved bill addressing medical marijuana reciprocity and pre-roll access—might look like a small adjustment on paper. In reality, it signals something bigger: a continued shift toward accessibility, usability, and normalization. At the center of the bill are two key ideas. First, allowing out-of-state medical cannabis patients to access New York’s program under certain conditions. Second, pushing regulators to formally allow pre-rolls within the medical system. Neither concept is entirely new—New York has already been moving in this direction—but the legislative reinforcement matters. It shows intent. For patients, reciprocity removes friction. New York sits in a dense corridor of movement—people travel between states daily. Whether it’s New Jersey, Connecticut, or beyond, patients don’t stop needing access when they cross state lines. This kind of policy acknowledges real-world behavior instead of forcing people into gray areas. The second piece—pre-rolls—is even more telling. Pre-rolls are one of the most accessible cannabis formats available. No setup, no additional tools, no learning curve. Just consistency and convenience. For medical users, especially those new to cannabis or looking for straightforward dosing, this matters. It lowers the barrier to entry. Zoom out, and the pattern becomes clear. New York isn’t just building a cannabis market—it’s refining how people interact with it. Less friction. More usability. Cleaner entry points. At Elevated Club NYC, we’ve always leaned into that same philosophy: Quick. Easy. Discreet. The industry is catching up to what consumers have been asking for all along—simplicity without compromise. Because the future of cannabis isn’t just about what you’re getting. It’s about how effortlessly you can get it. Stay Elevated.

By Justice — Elevated Club NYC For the first time since legalization, Denver’s cannabis market is slowing down. After more than a decade of growth, headlines are calling it a “recession.” But let’s be clear—this isn’t the industry failing. This is what maturity looks like. Denver was one of the first cities to legalize recreational cannabis back in 2014. It became the blueprint. Tourists flew in just to experience legal weed. Dispensaries printed money. Brands didn’t need identity—just inventory. But that era is over. Today, cannabis is legal across much of the country. The tourism advantage is gone. Supply has exploded. Prices have dropped. And operators are facing tighter margins than ever before. What used to be a gold rush is now a competitive, efficiency-driven market. This is the part most people misunderstand: the demand didn’t disappear—the market evolved. Cannabis in Denver has become a commodity. When everyone is selling the same thing, the only way to compete is price. And price wars don’t build sustainable businesses—they erase them. Now shift that lens to New York. NYC isn’t Denver. Not yet. This market is still early. Still forming. Still defining what premium actually means. And that’s where the opportunity is. Because the lesson from Denver is simple: if you don’t build a brand early, you become replaceable later. At Elevated Club NYC, we’re not just focused on product—we’re focused on experience, consistency, and trust. No storefront. No lines. No guesswork. Just curated quality, delivered discreetly across the city. While other markets are correcting, NYC is still being shaped. The businesses that understand culture, presentation, and consumer education will be the ones that last when this market inevitably matures. Denver shows us the future—but it also shows us what to avoid. This isn’t a warning. It’s a blueprint. Education is elevation.

By Justice — Elevated Club NYC New York legalized cannabis with a clear vision: equity, access, and a regulated market that could replace decades of prohibition. But in 2026, the reality on the ground tells a more complex story. The legal market is growing—but it’s still competing with a system that never stopped. Across New York City, enforcement against unlicensed smoke shops has intensified. Raids, product seizures, and storefront shutdowns have become more common as regulators try to bring order to a crowded and chaotic retail landscape. The goal is simple: protect licensed operators and push consumers toward legal channels. But the impact is mixed. For every shop that closes, another seems to open, reflecting how deeply rooted the informal market still is. At the same time, licensed businesses are facing real operational pressure. High taxes, strict compliance requirements, and expensive startup costs make it difficult to compete on price. For consumers, that difference is noticeable. Legal products often come at a premium, while unlicensed options remain cheaper and more accessible. Convenience still drives behavior—and in New York, convenience often wins. Delivery is a perfect example. The state allows licensed cannabis delivery, but the rules are tight. ID verification, tracking systems, and geographic restrictions create a controlled environment. Meanwhile, gray-market delivery services continue to operate with fewer barriers, offering speed and simplicity that many consumers are already used to. The result is a split ecosystem where legal infrastructure exists, but informal networks still dominate. Dispensary expansion is happening, but slower than expected. The state prioritized social equity applicants, which is a step in the right direction, but rollout delays have limited how quickly the legal market can scale. In many neighborhoods, demand still outweighs legal supply, leaving space for unlicensed sellers to fill the gap. Tax revenue is growing, but not at the pace early projections promised. The state is generating significant income from cannabis, yet a large portion of potential revenue is still being lost to the illicit market. Regulators are aware of this and continue to adjust policies, looking for ways to make the legal system more competitive without compromising its structure. This is where New York stands today: not at the beginning, but not fully established either. Legal cannabis exists, but it’s still proving itself in real time. From my perspective, the conversation isn’t just about legal versus illegal—it’s about experience. Price, access, trust, and convenience all play a role in where people choose to buy. If the legal market wants to lead, it has to meet consumers where they are, not where policy expects them to be. Because in New York, cannabis isn’t just a product—it’s a culture. And culture doesn’t wait for regulation to catch up. Stay Elevated.

By Justice — Elevated Club NYC Across the United States, regulators are beginning to close one of the most controversial loopholes in the modern cannabis market: intoxicating hemp products. Over the past few years, compounds like Delta-8 THC, Delta-10 THC, and high-THCA hemp flower have exploded in popularity, appearing in gas stations, smoke shops, convenience stores, and online marketplaces. The surge happened largely because of the 2018 Farm Bill, which legalized hemp as long as it contained less than 0.3% Delta-9 THC by dry weight. That definition created a gray area. While Delta-9 THC was restricted, other cannabinoids derived from hemp could still produce intoxicating effects. Manufacturers quickly took advantage of this gap, creating products that technically met federal hemp standards while still delivering a psychoactive experience. As a result, a parallel cannabis economy emerged outside of licensed dispensaries. Now that loophole is beginning to close. Several states are moving to regulate or outright ban intoxicating hemp products. In places like Maryland and Illinois, governments are requiring these products to be sold only through licensed cannabis retailers rather than gas stations or convenience stores. Other states are considering stricter rules that would treat Delta-8 and similar cannabinoids the same way traditional THC products are regulated. At the federal level, lawmakers are also considering updates to hemp regulations that would count total THC, including THCA and other THC isomers, rather than just Delta-9. If implemented, this change could significantly reshape the hemp marketplace. For licensed cannabis operators, these changes could level the playing field. Many businesses in regulated markets have long argued that intoxicating hemp products created unfair competition because they bypassed testing requirements, licensing fees, and cannabis taxes. The coming year may mark a turning point. As regulators tighten the rules around hemp-derived THC, the line between hemp and cannabis could become clearer than it has been since federal legalization of hemp began. For consumers and businesses alike, the message is simple: the era of “gas station weed” may be coming to an end. Education is elevation. Stay Elevated.

For decades, cannabis has existed in a strange space in American law. Millions of people use it, dozens of states have legalized it in some form, and a massive industry has grown around it. Yet at the federal level, cannabis regulation still moves cautiously — especially when it comes to the role of the U.S. Food and Drug Administration . The FDA’s position on cannabis is often misunderstood. While cannabis may be legal for medical or adult use in many states, the FDA regulates products that claim medical benefits, food safety, and pharmaceuticals. Under the agency’s framework, cannabis itself has not been approved as a medicine to treat diseases or medical conditions. What the FDA has approved are a handful of specific cannabinoid-based pharmaceuticals that went through the traditional drug-approval process. One of the most well-known examples is Epidiolex, a purified CBD medication prescribed for rare forms of epilepsy. The FDA has also approved synthetic cannabinoid drugs such as dronabinol and nabilone for specific medical uses like chemotherapy-related nausea. These products were approved because they were tested through clinical trials, reviewed for safety, and manufactured under strict pharmaceutical standards. That distinction matters. Across the country, consumers can find thousands of cannabis and hemp products marketed for wellness, relaxation, sleep, or pain relief. But from the FDA’s perspective, most of these products exist outside the federal drug approval system. That means the agency has not verified their safety, effectiveness, dosing consistency, or manufacturing quality in the same way it does for prescription medications. CBD is a particularly complicated case. When the 2018 Farm Bill legalized hemp — defined as cannabis with less than 0.3% delta-9 THC — it opened the door for a massive CBD market. Oils, drinks, gummies, and topicals quickly appeared everywhere from wellness boutiques to gas stations. But the FDA maintains that current food and supplement regulations were not designed for compounds like CBD, especially because CBD has already been studied as a pharmaceutical ingredient. In 2023, the FDA publicly stated that existing regulatory pathways for foods and dietary supplements are not appropriate for CBD products and that a new framework may require action from Congress. In other words, federal regulators believe the market has grown faster than the rules governing it. Another area drawing attention is intoxicating hemp derivatives, particularly delta-8 THC. These products are often synthesized from hemp-derived cannabinoids and sold in packaging that resembles traditional snack foods or candy. Federal regulators have issued warnings to companies producing these products, citing concerns about consumer confusion, child safety, and reports of adverse health events. All of this reflects a broader issue: cannabis regulation in the United States is fragmented. States control retail cannabis markets, while federal agencies oversee drug safety, interstate commerce, and pharmaceutical approvals. That overlap creates a regulatory gray area where cannabis businesses operate under state law but still exist outside many federal regulatory systems. At the same time, federal policy may be shifting. The Drug Enforcement Administration  has begun reviewing a proposal that could move cannabis from Schedule I to Schedule III of the Controlled Substances Act. If that change happens, it could reduce barriers to scientific research and potentially reshape how cannabis is studied and regulated in the future. For the cannabis industry, the message from federal regulators is clear: science and regulation are catching up to the market, but they are doing so slowly. At Elevated Club NYC, we believe education is part of elevation. The cannabis conversation is evolving — from prohibition, to legalization, to regulation. Understanding how agencies like the FDA view cannabis helps consumers, businesses, and policymakers navigate the next phase of the industry. Because the future of cannabis won’t just be shaped by culture or demand. It will also be shaped by science, regulation, and the rules that determine how cannabis products are studied, labeled, and sold.

By Justice — Elevated Club NYC New research suggests that compounds found in cannabis could help treat one of the most common chronic health conditions affecting adults today: metabolic dysfunction-associated steatotic liver disease (MASLD) — commonly known as fatty liver disease. MASLD affects roughly one-third of adults worldwide, making it the most common chronic liver disorder. The condition is closely linked to obesity, insulin resistance, and metabolic syndrome, and it currently has very limited pharmaceutical treatment options. A recent study published in the British Journal of Pharmacology examined how two non-intoxicating cannabinoids — CBD (cannabidiol) and CBG (cannabigerol) — affect liver metabolism. Researchers discovered that these compounds significantly reduced fat buildup in the liver and improved metabolic health in experimental models. Unlike THC, the compound responsible for cannabis’s psychoactive effects, CBD and CBG do not produce a “high.” This makes them especially interesting for potential medical therapies that could be used long-term. The researchers identified a process called “metabolic remodeling.” In simple terms, the cannabinoids helped the liver produce more energy and improve cellular cleanup systems that break down excess fats. This allowed the liver to function more efficiently even under metabolic stress. CBG appeared particularly promising in the study. Scientists observed reductions in body fat, LDL cholesterol levels, and improvements in insulin sensitivity — key markers tied to metabolic disease. However, experts caution that these findings are still preclinical, meaning they were observed in controlled laboratory models. Human clinical trials will be necessary before cannabis-derived therapies could become standard treatments. Still, the research highlights something the cannabis conversation often misses: the plant contains dozens of biologically active compounds, many of which are still being studied for their medical potential. For an industry often reduced to THC percentages and strain names, discoveries like this show the deeper scientific frontier behind cannabis. At Elevated Club NYC, we believe education is elevation. As cannabis research continues to expand, understanding the plant beyond recreational use will become increasingly important — not just for consumers, but for the future of medicine. Stay Elevated.

By Justice — Elevated Club NYC One of the biggest arguments critics make about cannabis legalization is that the illegal market will always dominate. But new research suggests the opposite may be happening. A recent study from the Columbia University Mailman School of Public Health found that states with recreational cannabis laws are seeing measurable declines in illegal cannabis activity. Researchers analyzed more than 286,000 cannabis seizures by law enforcement between 2010 and 2023, linking those records with state cannabis policies across the United States. The results were striking. States that adopted recreational cannabis laws in addition to medical programs saw a 45% reduction in cannabis seizure counts compared with states that only allowed medical marijuana. Seizure data isn’t just a policing statistic — it’s often used as a proxy for illegal market activity. When seizures fall dramatically, it may signal that fewer illegal transactions are taking place or that consumers are moving into the regulated market. Researchers say the shift likely comes from two major factors. First, legal access changes consumer behavior. When people can purchase tested, labeled cannabis products from licensed retailers, many prefer that option over unregulated sources. Second, law enforcement priorities evolve once cannabis becomes legal. Police departments in legal states often redirect resources away from cannabis enforcement and toward more dangerous drugs such as fentanyl or synthetic opioids. That doesn’t mean illegal cannabis disappears entirely. Unlicensed operators still exist, especially in markets where taxes are high or licensing is limited. But the research suggests legalization can significantly reduce the scale of underground activity. As of today, 24 U.S. states and Washington, D.C. have legalized recreational cannabis, while medical cannabis programs now exist in about 40 states. The bigger picture is becoming clearer: regulated cannabis markets aren’t just about access or tax revenue. They may also be reshaping the structure of the cannabis economy itself. For consumers, legalization often means safer products and better transparency. For policymakers, it offers a potential path away from decades of ineffective prohibition. And for the cannabis industry, it reinforces a simple reality: when legal markets are built correctly, the underground market starts to lose its power. Education is elevation.

By Justice — Elevated Club NYC Texas may soon shut down one of the fastest-growing corners of the cannabis economy: smokable hemp flower. New rules proposed by the Texas Department of State Health Services could effectively ban the sale of smokable cannabis products by changing how THC is calculated in hemp. At the center of the issue is THCA, the naturally occurring compound in cannabis that converts into THC when heated. While hemp is federally legal as long as it contains less than 0.3% Delta-9 THC, most cannabis flower actually contains THCA that becomes THC when smoked. If Texas regulators begin counting THCA toward the THC limit, most smokable hemp products currently sold in stores would instantly become illegal. For the hemp industry in Texas, the impact could be massive. The state has more than 9,000 registered retailers selling hemp products, from smoke shops to convenience stores.   The proposed rules would also dramatically raise licensing fees for manufacturers and retailers — in some cases increasing costs by thousands of percent — which many small operators say would force them out of business. Supporters of the crackdown argue the hemp market has become a loophole that allows potent THC products to be sold in a state where recreational cannabis remains illegal. Texas officials say stronger regulations, age restrictions, and tighter testing standards are necessary to protect consumers and keep intoxicating products away from minors. But critics say banning smokable hemp will not eliminate demand — it will simply push consumers toward unregulated markets. For many retailers, smokable hemp flower is the backbone of their business, and removing it could wipe out a multi-billion-dollar industry almost overnight. The situation highlights the complicated reality of cannabis policy in the United States. Federal hemp legalization created a booming market for cannabinoids like Delta-8 and THCA, but many states are now scrambling to regulate or restrict these products after they spread far beyond CBD wellness shops. For the broader cannabis industry, Texas is a reminder that legalization in America remains a patchwork of laws and politics. While states like New York are expanding regulated cannabis markets, others are tightening rules around hemp-derived THC products. One thing is clear: the cannabis conversation in America is far from settled. Education is elevation. Make a cover for this article muji style

A new experiment in cannabis access is unfolding in Arizona—and it might signal where the industry is headed next. Independent living communities across the state are preparing to install digital marijuana kiosks designed specifically for senior residents, allowing them to browse cannabis products, learn about effects, and place delivery orders directly from their communities. The kiosks are part of a partnership between cannabis retailer Life Is Chill and technology company LoveBud, which plans to deploy interactive terminals in participating senior housing developments. Residents will be able to explore menus, read product information, and order cannabis from licensed dispensaries without needing to travel to a store. The idea addresses a real demographic shift happening across the United States: seniors are one of the fastest-growing groups of cannabis consumers. Many older adults report using cannabis for pain relief, sleep, relaxation, and mood support.  But for many seniors—especially those living in retirement communities—visiting a dispensary isn’t always easy. Mobility issues, transportation challenges, and lingering stigma can create barriers to access. The kiosk model attempts to solve those problems. The terminals provide guided, educational ordering experiences, helping residents understand products like edibles, tinctures, and flower before placing an order. Once a purchase is made, the cannabis is delivered through a licensed dispensary partner, keeping the system compliant with Arizona’s regulated cannabis market. From a business perspective, the model also creates new opportunities for the industry. Smaller dispensaries gain a new sales channel, while retirement communities gain a structured way to address resident interest in cannabis without operating a dispensary themselves. The concept also reflects a broader cultural shift. Just a decade ago, cannabis conversations rarely included older adults. Today, the reality looks different: legalization across dozens of states and growing public awareness of cannabinoids have made cannabis part of mainstream wellness discussions—including among retirees. For the cannabis industry, innovations like these kiosks highlight an important trend: the market is expanding beyond traditional consumers. From medical patients to wellness users to retirees looking for natural relief, cannabis is increasingly meeting people where they are—sometimes quite literally. Whether the Arizona pilot becomes a nationwide trend remains to be seen. But one thing is clear: the future of cannabis retail may not always look like a dispensary storefront. Sometimes it might look like a touchscreen kiosk down the hall from the shuffleboard court.

New York’s legal cannabis market is expanding at a pace few predicted. Just a few years after adult-use sales officially launched, the state now finds itself facing an unexpected problem: demand may soon exceed supply. According to regulators and industry analysts, New York could face a shortage of as much as 365,000 pounds of cannabis over the next year if production doesn’t increase quickly enough. The rapid growth of dispensaries and the surge in consumer demand have created a market that’s moving faster than cultivators can keep up with. When adult-use cannabis first launched in New York in December 2022, the biggest concern wasn’t shortages—it was the opposite. Farmers who were part of the state’s initial cultivation program struggled with excess inventory because the rollout of legal dispensaries was slow. Lawsuits, licensing delays, and regulatory hurdles meant that many growers had cannabis ready to sell but few stores open to carry it. Fast forward to 2026 and the situation has flipped. Hundreds of dispensaries are now operating across the state, and consumer demand is rising quickly as cannabis becomes more normalized. Legal sales have already reached billions of dollars since legalization, and analysts project the market could generate around $2.6 billion in sales in 2026 alone, with long-term forecasts pushing that number even higher. To prevent supply shortages, New York’s Office of Cannabis Management (OCM) is considering several steps to increase production. These include issuing new cultivation licenses, allowing existing growers to expand their canopy size, and accelerating approvals for additional cannabis farms. The goal is simple: keep the legal market stocked with high-quality products so consumers don’t return to the illicit market that dominated New York for decades. But the potential shortage also highlights something important about the state’s cannabis industry—it’s finally gaining momentum. For years, critics argued that New York’s rollout was too slow and overly complicated. Now, the opposite challenge is emerging. Demand is strong, new businesses are opening, and the legal market is beginning to take shape. For consumers, this could mean higher prices in the short term if supply tightens. For growers and brands, it represents a major opportunity as the state expands cultivation capacity. New York is still in the early chapters of legalization, but the trajectory is clear. What started as a cautious rollout is rapidly turning into one of the most significant cannabis markets in the United States. And if current projections are correct, the next few years could define how the entire East Coast cannabis industry evolves. Education is elevation.

A recent viral story out of New Jersey sparked an unusual conversation at the intersection of cannabis culture and classic American tradition. A local Girl Scout troop gained national attention after setting up a cookie stand outside a legal cannabis dispensary, leading to massive cookie sales—and an even bigger debate online. The situation was simple: customers leaving the dispensary were already in a snack-friendly mood, and Girl Scout cookies are arguably one of the most recognizable treats in America. Unsurprisingly, the booth reportedly sold out quickly. For many observers, it felt like an obvious example of market timing. Where there’s demand for snacks, cookies tend to follow. But the viral moment also raised questions about optics. Some critics argued that having children selling cookies near a cannabis retailer blurred the line between youth organizations and an adult-only industry. Others pointed out that the booth was legally set up outside the store, not inside, and that legal cannabis businesses operate like any other regulated retail environment. The story quickly spread across social media and major news outlets, not because of any wrongdoing, but because it highlighted something bigger: cannabis is increasingly part of everyday life in many states. What once existed entirely in the shadows now sits next to coffee shops, bakeries, and grocery stores. In New Jersey and New York, legal cannabis markets are expanding rapidly. As dispensaries become more common in neighborhoods, moments like this reflect a cultural shift. Cannabis is no longer just a counterculture symbol—it’s becoming part of the broader retail ecosystem. Of course, conversations about responsible boundaries still matter. Cannabis is an adult product, and protecting youth spaces will always be important. But viral moments like this also show how society is still adjusting to legalization and figuring out what “normal” looks like in this new landscape. From a cultural standpoint, the internet reaction says a lot. Some people saw humor in the situation. Others saw a marketing opportunity. And many saw it as a sign of how much the cannabis industry has evolved. At Elevated Club NYC, we view moments like this as reminders of how quickly the conversation around cannabis continues to change. Education, responsible use, and transparency remain essential as the industry grows. Because legalization isn’t just about selling cannabis—it’s about how cannabis fits into the everyday world around us. And sometimes, apparently, that world includes a box of Thin Mints. By Justice — Elevated Club NYC Quick. Easy. Discreet.